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Abstract
Setting
A high proportion of notified tuberculosis cases in the Philippines are clinically diagnosed
(63%) as opposed to bacteriologically confirmed. Better understanding of this phenomenon
is required to improve tuberculosis control.
Objectives
To determine the percentage of smear negative presumptive tuberculosis patients that
would be diagnosed by GeneXpert; compare clinical characteristics of patients diagnosed
as tuberculosis cases; and review the impact that the current single government physician
and a reconstituted Tuberculosis Diagnostic committee (expert panel) may have on tubercu-
losis over-diagnosis.
Design
This a cross-sectional study of 152 patients 15–85 years old with two negative Direct Spu-
tum Smear Microscopy results, with abnormal chest X-ray who underwent GeneXpert test-
ing and review by an expert panel.
Results
Thirty-two percent (48/152) of the sample were Xpert positive and 93% (97/104) of GeneX-
pert negatives were clinically diagnosed by a single physician. Typical symptoms and X-ray
findings were higher in bacteriologically confirmed tuberculosis. When compared to the
GeneXpert results the Expert panel’s sensitivity for active tuberculosis was high (97.5%, 39/
40), specificity was low (40.2%, 35/87).
PLOS ONE | https://doi.org/10.1371/journal.pone.0227093 December 30, 2019 1 / 11
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Abong J, Dalay V, Langley I, Tomeny E,
Marcelo D, Mendoza V, et al. (2019) Use of
GeneXpert and the role of an expert panel in
improving clinical diagnosis of smear-negative
tuberculosis cases. PLoS ONE 14(12): e0227093.
https://doi.org/10.1371/journal.pone.0227093
Editor: Frederick Quinn, The University of Georgia,
UNITED STATES
Received: May 17, 2019
Accepted: December 12, 2019
Published: December 30, 2019
Copyright: © 2019 Abong et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data in
the study are already included in the tables of the
manuscript. The data presented within our
manuscript were entirely anonymized. However
individual level data cannot be shared publicly
because the data belongs to the patients and is
under strict confidentiality as stated in the informed
consent. For data requests they may contact our
Independent Ethics Committee Chair Dr. Melchor
Victor G. Frias IV through (046) 481-8000 loc.
8042 or email at mgfrias@dlshsi.edu.ph or our
Data Protection Officer Mr. Alex B. Rodriguez
Conclusion
Using the GeneXpert would increase the level of bacteriologically confirmed tuberculosis
substantially among presumptive tuberculosis. An expert panel will greatly reduce over-
diagnosis usually seen when a decision is made by a single physician.
Introduction
The Philippines ranks as 4th globally in tuberculosis (TB) incidence among the high-burden
countries, and 5th among MDR-TB [1]. In 2016, the estimate of TB incidence among Filipino
adults was 554 per 100,000 (95% C.I. 311─866) [2].
Local and international experts have noted the high level of TB cases that are Clinically
Diagnosed (CD) (approximately 61% of notified cases in 2017) in the Philippines [2]. A better
understanding of this phenomenon will play a major role in shifting the battle for TB control
in the Philippines.
GeneXpert MTB/RIF (Xpert), introduced in the Philippines in 2011, is a rapid diagnostic
test with high sensitivity and specificity for TB. Despite the availability of Xpert, direct sputum
smear microscopy (DSSM) remains the primary diagnostic tool for pulmonary tuberculosis
(PTB), although the national program is gradually shifting to Xpert.
Cavite, one of the largest provinces in the Philippines, has consistently low detection rates
and high CD PTB [3,4]. Bacteriological confirmation by TB Culture from smear-negative
patients is 7% however it is not routinely requested. Instead, smear negative pulmonary tuber-
culosis (SNPT) cases are referred to a single government physician for further evaluation and
treatment recommendation.
The TB Diagnostic Committee (TBDC), composed of a local panel of experts from private
and public sectors, was created in the 1990’s by the Department of Health (DOH) to improve
the quality of diagnosis of sputum smear-negative cases using chest X-ray findings of patients
from the TB Directly Observed Treatment (DOTS) Facility. The shortage of trained and quali-
fied specialists especially in rural and remote areas in the Philippines however resulted in a lon-
ger turnaround time and delays in diagnosis and treatment. This led to a change in the
Philippine Manual of Procedures which then gave an option of a single physician (SP) making
a decision instead of a TBDC. This may have contributed to the steady rise of clinical diagnosis
in recent years. Oftentimes an SP (sometimes acting as a ‘one-man TBDC’) can decide on
diagnosis and treatment of clinical TB but some TBDCs continue to function [5].
This study is part of a larger project called the Newton Agham Fund Impact assessment of
diagnostic algorithms and tools for multi drug resistant (MDR-TB) and drug sensitive tubercu-
losis (TB) in the Philippines (TB-FIT). The primary aim of this study is to evaluate the role of
GeneXpert in the diagnosis of BC TB among SNPT cases in a high CD prevalent area of Cavite.
Methods
Setting
The study was conducted in two urban-based public DOTS centers in the province of Cavite
(Dasmariñas—659,019 population, Trece Martires City -155,713 population)[6]. These two
facilities were chosen due to the high volume of patients and accessibility of Xpert testing. The
study was conducted with the approval of the Provincial Health Office and the City Health
Offices (CHO) of the two sites.
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Eligible patients
Patients seeking consult at Dasmariñas City and Trece Martires CHOs DOTS facilities with
two negative sputum smears and with abnormal chest X-ray, were recruited into the study.
Procedures
Direct Sputum Smear Microscopy was performed using Ziehl-Neelsen microscopes. Patients
without chest X-rays or without film available, were requested to obtain a chest X-ray at the
CHO/De La Salle. Eligible patients were offered the Xpert test and instructed on the test evalu-
ation and sputum collection procedure.
Field coordinators secured informed consent and interviewed the eligible patients. A pre-
tested tool was used to collect baseline data on demographics, clinical symptoms and chest X-
ray. X-ray films were reproduced using a 1080 x 1920 resolution and 18 megapixels camera. X-
ray results were classified based on standard radiologic reading of chest films utilized by certi-
fied local radiologic society (Philippine College of Radiology) [7–9]. All Xpert tests were per-
formed in De La Salle Medical and Health Sciences Institute—Center for TB Research by the
National TB Reference Laboratory trained medical technologist with a 100% Data Quality
Check performance (conducted every quarter). Patients were instructed on sputum collection
according to the National TB Program Manual of Procedures [5], sputum samples of patients
were collected every Tuesday and Wednesday for Trece Martires CHO and daily for Dasmar-
iñas CHO and stored at -20˚C until testing.
Xpert testing was performed according to the manufacturer’s procedure. Those who were
Xpert negative were referred to the corresponding SP of the participating sites for final disposi-
tion. Patients recommended for treatment by the SP, were considered as CD TB. In addition, a
panel of experts consisting of 3 certified pulmonologists, a microbiologist and a radiologist
reviewed the clinical profile and chest X-rays of all study participants. The panel was unaware
of the Xpert results prior to their evaluations. If there was a disagreement with the diagnosis
among the members, consensus of the majority (at least 3 of 5 panel members) was needed to
carry out the diagnostic recommendation.
Physicians were provided with the results of the Xpert prior to patient’s consult. Treatment
statuses of the patients were obtained within a month after notification of Xpert result.
Sample size calculation
A sample size of 152 SNPT patients were included in the study to be able to have 95% confi-
dence level of estimating percentage of Xpert positivity at 21.3% [10] with relative precision of
30%, participation rate of 85%. The computed sample size was proportionately allocated to
Dasmariñas CHO 1 and Trece Martires CHO using 2015 data on number of smear negatives
from the two sites.
Data analysis
The survey was paper-based and EPI Info for Windows v7.2 was used for data entry and analy-
sis. A Chi-square test was used to determine significant differences in categorical variables
such as demographic and clinical characteristics between those Xpert positive and CD patients,
while a t-test was used to determine significant differences in continuous variables such as age
and number of symptoms. Level of significance was set at p-value less than 0.05.
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Ethics statement
This study was approved by the Independent Ethics Committee of the De La Salle Medical and
Health Sciences Institute with the approval number of–DLSHSI-IEC (2017)– 02 -01- A. All
participants were provided a written informed consent.
Results
From June to August 2017, we recruited 152 patients who fulfilled the study’s inclusion crite-
ria. They were all smear-negative participants with an abnormal chest X-ray, and all consented
to participate and be tested with Xpert. The mean age was 40.3 years (range 15–85 years);
62.7% were male.
Thirty-two percent (48/152, 95% CI 24.6, 39.3) tested positive on Xpert and were enrolled
in treatment at their corresponding DOTS facility. An average of 3 smear-negative presump-
tive PTB patients needed to be Xpert tested to detect 1 Bacteriologically Confirmed (BC) PTB.
One rifampicin resistant case was detected and enrolled at the Programmatic Management of
Drug-resistant TB Centre (PMDT) for treatment.
Ninety-seven of the 104 (93.3%) smear-negative, Xpert negative patients were CD by SP
and were enrolled for treatment. Of the remaining seven, four were diagnosed with no PTB,
three patients needed further diagnostic tests (repeat chest X-ray, chest CT scan. These three
were lost to follow-up (LTFU). Only 89 CD patients were enrolled to treatment (Fig 1). The
Fig 1. Diagnostic outcome of 152 smear negative presumptive TB patients.
https://doi.org/10.1371/journal.pone.0227093.g001
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remaining 8 patients were not enrolled due to refusal to treatment (1 patient), diagnosed with
no active TB (2 patients), LTFU (4 patients) and 1 died of a non-TB related heart condition
(Fig 1).
Tables 1–4 show the demographic profile, reason for consultation, Body Mass Index and
symptoms of the 145 smear-negative TB patients, (48 Xpert positive and 97 clinically diag-
nosed cases).
Table 1 shows that the baseline characteristics of the two groups were similar except for the
Body Mass Index. A significant number of patients with positive Xpert results exhibited abnor-
mal Body Mass Index, more than half were underweight.
In Table 2 a significantly higher proportion of patients who went to the DOTS clinic for
employment reasons were CD, compared to those who consulted for check-up (91.7% vs 62%)
(p-value = 0.004).
All BC patients were symptomatic with an average of 5 symptoms while the CD presented
an average of 3 (p-value<0.001). Prevalence of the following symptoms were higher among
the BC patients than CD: cough (p-value = 0.002), loss of appetite (p-value = 0.013), weight
loss (p-value <0.001), shortness of breath (p-value = 0.016). Cough, weight loss, and hemopty-
sis were 4 times (3.7 to 4.4. OR) more likely in BC than in CD (Table 3).
Table 1. Demographic profile of bacteriologically confirmed through Xpert (BC) and clinically diagnosed (CD) among smear negative presumptive TB patients in
TB DOTS facility, Dasmariñas and Trece Martirez City, 2017.
Characteristics BC (n = 48) CD (n = 97) Chi-Square
p-valuen % n %
Sex Female 14 29.2 40 41.2 0.157
Male 34 70.8 57 58.8
Age Group < 45 yo 36 75 57 58.8 0.055
= >45 yo 12 25 40 41.2
Mean (SD) Age in years 36.8 (13.8) 40.9 (18.6) 0.132
Employment Yes 21 43.8 37 38.1 0.517
No 27 56.3 60 61.9
Educational Attainment Not attended school / Primary School 14 29.2 32 33 0.642
Secondary school / University/ College 34 70.8 65 67
Body Mass Index Category Underweight 27 56.3 28 28.9 0.009
Normal 19 39.6 55 56.7
Overweight 1 2.1 11 11.3
Obese 1 2.1 3 3.1
Smoking Current smoker 12 26.1 27 28.4 0.476
Former smoker 5 100 5 5.3
Never smoked 29 63 63 66.3
Alcohol Drinker 28 58.3 54 55.7 0.761
Non-drinker 20 41.7 43 44.3
https://doi.org/10.1371/journal.pone.0227093.t001
Table 2. Diagnosis outcome of subjects who consulted for employment or check-up among smear negative pre-
sumptive TB patients in TB DOTS facility, Dasmariñas and Trece Martirez City, 2017.
Reason for Consultation Diagnosis Outcome
BC CD Total
n % n % n %
For employment 2 8.3 22 91.7 24 100
Check-up 46 38.0 75 62.0 121 100
Total 48 33.1 97 66.9 145 100
https://doi.org/10.1371/journal.pone.0227093.t002
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Among the Xpert negative CD patients the most common symptoms included cough and
shortness of breath/chest pain (Table 3). 15 (15.4%) CD patients were asymptomatic, 8 con-
sulted for employment purposes, 2 were referred by private physicians, and 5 were walk-ins.
Chest X-rays of all patients were reviewed by the panel of experts. Radiologic findings of
extensive involvement, miliary TB, cavitation, pleural effusion, consolidation, fibrohazed,
opacities are significantly higher among BCs compared to CDs (p values<0.05) (Table 4)
Table 5 shows the Expert panel’s (EP) diagnosis compared to Xpert positivity of 127 pre-
sumptive smear negative patients. Twenty-five patients recommended for repeat chest X-ray
by the EP were not included in the computation.
Excluding those for further testing, the EP diagnosed active PTB in 39 of 40 Xpert positive
patients yielding a 98% sensitivity (based on Xpert as the gold standard), and further diagnosed
35 out of 87 Xpert negatives as non-active TB yielding a 40% specificity.
Of the 104 Xpert negative cases, the EP considered 52 cases, 28 of which were active PTB
cases and 24 indeterminate cases. According to the panel these 24 indeterminate cases should
be enrolled for treatment because of the presumption that it is better to treat them than leave
Table 3. Symptoms of bacteriologically confirmed through Xpert (BC = 48) and clinically diagnosed (CD = 97) among smear negative presumptive TB patients in
TB DOTS facility, Dasmariñas and Trece Martirez City, 2017.
TB Symptoms BC (n = 48) CD (n = 97) OR p-value
n % n % (95% CI)
Cough 43 90 64 66 4.4 (1.6, 12.3) 0.002
Weight loss 31 65 31 32 3.9 (1.9, 8.1) <0.001
Hemoptysis 12 25 8 8 3.7 (1.4, 9.8) 0.006
Night sweats 18 38 15 16 3.3 (1.5, 7.3) 0.003
Fever 20 42 18 19 3.1 (1.5, 6.8) 0.003
Loss of appetite 24 50 28 29 2.5 (1.2, 5.0) 0.013
Malaise 16 33 16 16 2.5 (1.1, 5.7) 0.021
Shortness of breath/chest pain 31 65 42 43 2.4 (1.2, 4.9) 0.016
Sputum Production 40 83 68 70 2.1 (0.9, 5.1) 0.085
No of symptoms
Mean (SD)
5 (2.3) 3 (2.2) – <0.001
https://doi.org/10.1371/journal.pone.0227093.t003
Table 4. Chest X-ray findings of bacteriologically confirmed through Xpert (BC = 48) and clinically diagnosed (CD = 97) among smear negative presumptive TB
patients in TB DOTS facility, Dasmariñas and Trece Martirez City, 2017.
Chest X-ray findings BC (n = 48) CD (n = 97) OR p-value
n % n % (95% CI)
Extensive Involvement / no cavitations 18 38 5 5 11.0 (3.8, 32.3) <0.001
Miliary TB 4 8 1 1 8.7 (0.9, 80.4) 0.023
Cavitation 15 31 5 5 8.4 (2.8, 24.8) <0.001
Pleural effusion 12 25 4 4 7.8 (2.3, 25.6) <0.001
Consolidation 20 42 11 11 5.6 (2.4, 13.1) <0.001
Fibrohazed densities 45 94 72 74 5.2 (1.5, 18.3) 0.005
Opacities, densities 31 65 26 27 4.9 (2.4, 10.5) <0.001
Suspected Pneumonia 12 25 11 11 2.6 (1.1, 6.4) 0.034
Hazy densities 32 67 50 52 1.9 (0.9, 3.9) 0.084
Fibrosis, pleural thickening 12 25 20 21 1.3 (0.6, 2.9) 0.549
Atelectasis 3 6 8 8 0.7 (0.2, 2.9) 0.669
Calcification 0 0 3 3 – –
https://doi.org/10.1371/journal.pone.0227093.t004
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them untreated since some may really have active TB. Yousang Ko et al. in 2018 evaluated the
diagnostic performance of the radiographic CT scan activities in predicting definite and over-
all PTB in patients with presumed PTB and found that 10% of indeterminate PTB were culture
confirmed [11].
Table 6 shows comparison between an SP and EP’s diagnosis. Excluding 20 subjects that
were recommended for further test by either the SP or EP, among the 84 smear and Xpert neg-
ative patients with abnormal X-ray, 80 (95%) were CD by a single physician of whom only 51
(61%) were considered CD by the EP.
Discussion
Xpert positivity among smear negative presumptive tuberculosis
Across two DOTS centers in Cavite, testing SNPT cases with GeneXpert returned a bacterio-
logical confirmation in 31% of cases (i.e. we only need to test 3 smear negative cases to detect 1
BC). This percentage is consistent with the range of figures from other studies (21% - 36.5%).
In a fee paying hospital in Nepal 21% of smear negative cases were bacteriologically con-
firmed by Xpert and the number needed to test was five [10]. A higher percentage (34.9%) of
smear negatives with positive Xpert result was reported in a hospital-based setting in India,
needing 2.8 to be tested to detect one positive Xpert SNPT [12]. Among culture-positive,
smear-negative patients, Lombardi reported an increased TB detection of 36.5% by Xpert [13].
Comparison of clinical and radiologic features of BCs and CDs
Known clinical predictors of PTB such as cough, weight loss, hemoptysis and classic radiologic
findings seen on x-ray, were observed among many Xpert positive cases as expected [14,15].
There was a significant percentage of smear and Xpert negative cases who were diagnosed to
have SNPT and were enrolled to treatment.
Table 5. Diagnosis of expert panel and Xpert results of smear negative presumptive TB patients in TB DOTS
facility, Dasmariñas and Trece Martirez City, 2017.
Expert Panel (EP) Xpert Result
MTB Detected MTB Not Detected Total
n % n % n %
Active TB / Indeterminate 39 81 52 50 91 60
Inactive TB / No TB / Other lung disease 1 2 35 34 36 24
For Further Test 8 17 17 16 25 16
Total 48 100 104 100 152 100
https://doi.org/10.1371/journal.pone.0227093.t005
Table 6. Comparison of diagnosis of expert panel vs a single physician diagnosis of presumptive smear negative
patients among smear negative presumptive TB patients in TB DOTS facility, Dasmariñas and Trece Martirez
City, 2017.
Single Physician (SP) Expert Panel (EP)
Active TB /
Indeterminate
Inactive TB / No
TB / Other lung
disease
For Further Test Total
n % n % n % n %
CD 51 98 29 83 17 100 97 93
No TB 0 0 4 11 0 0 4 4
For Further Test 1 2 2 6 0 0 3 3
Total 52 100 35 100 17 100 104 100
https://doi.org/10.1371/journal.pone.0227093.t006
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Three features may have contributed to the high SNPT. Firstly, clinical diagnosis of SNPT
relied on chest X-ray findings as demonstrated among fifteen asymptomatic smear and Xpert
negative cases who were diagnosed based on chest X-ray findings of apical infiltrates/densities.
Secondly, the study inclusion criteria required an abnormal chest X-ray, which increased the
likelihood of being CD, reaching 93% of all smear and Xpert negative subjects diagnosed as
CD by the SP. Thirdly, there was a high percentage of CD cases among subjects whose consul-
tation was for employment purposes.
Single physician versus expert panel
Based on the NTP Manual of Procedures, the TBDC or a Physician may diagnose patients as CD.
This was introduced in 2014 due to slow turnaround times of the TBDC decisions which delayed
treatment [16]. While SP may hasten the process of decision-making avoiding potential pitfalls of
delays of convening a panel, we found that this may also be contributing to over-diagnosis and
high treatment enrolment. On the “patient pressure” side, local efforts are being made to harmo-
nize employment policies through inter-agency coordination (however this does not apply to for-
eign based employment). The 5-member EP created for the study to simulate a fully functioning
TBDC evaluated all the participants’ chest X-ray films and their clinical history. To address some
of the challenges facing the present TBDC, establishing an eTBDC (electronic TBDC) that doesn’t
need face to face meeting may be a good alternative to reduce turn-around time and unnecessary
delays. The eTBDC could meet through web conferencing at a time convenient to the members
which would eliminate travel time and cost. Through this method, detailed information about
symptomatology and X-ray finding which, in this study, were significantly found to be present in
Xpert positive patients will help toward a more accurate diagnosis of TB. The eTBDC has been
studied and piloted in the Philippines and was found to have great potential [17].
Using a published sensitivity of 67% and specificity of 98% [18] of Xpert among the 152
smear-negative cases for which we have results, two patients would be estimated to be unnec-
essarily treated (false positives). The estimated number of patients with TB disease that would
be missed by Xpert in the 152 population is 23. Although it’s not possible in this analysis to
determine the actual TB status of individual patients it is interesting to note the EP identified
28 additional active PTB cases which is not dissimilar to the 23 calculated above and suggests
the EP was able to identify most of these cases without generating high levels of over diagnosis.
The higher proportion of CD patients among those attending pre-employment ‘fit to work’
checks supports the hypothesis that there are non-medical factors leading to physicians enroll-
ing patients onto TB treatment. The authors believe the high CD rate among those subjects is
largely due to patient-pressure, with patients seeking to be placed on treatment as a way of
being cleared as fit to work. The study sites are industrialized areas in Cavite where several
industrial zones are located, and similarly in surrounding municipalities. Chest X-ray is a
mandatory pre-employment procedure [5], and those with suspicious chest X-ray results are
referred to physician specialists or DOTS centers. Patients with indeterminate findings are typ-
ically advised to get a repeat X-ray after 3–6 months, delaying medical clearance by issuance of
a ‘fit to work’ certificate. In this case this delay would cost the applicant their job position,
greatly impacting both the patient and their family, resulting in both economic loss and poten-
tially long lasting mental and physical health implications. These considerations likely pose a
serious challenge to TB DOTS physicians/TBDCs when diagnosing such patients.
Over-diagnosis leads to additional health system and direct patient costs. Patients incur
costs because of repeated visits to health centers, and exposure to potentially serious side
effects from unnecessary drugs. Patients misdiagnosed to have TB may actually have another
serious illness–e.g. cancer that requires immediate attention.
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In this study an SP made decisions on clinical diagnosis. A fully represented TBDC exem-
plified by the EP, may be able to diagnose correctly those with active TB (SNPT) missed by
Xpert. This study suggests that a fully represented TBDC is still useful to address missed cases
not identified by available diagnostic tests including Xpert and should be the preferred option
in diagnosing SNPT.
Recently, the WHO [19] released a consolidated summary of recommendations for the use
of X-ray for the diagnosis of TB advocating its widespread use in increasing detection rates for
TB in high burden countries. The widespread use of X-ray for screening and improving the
case detection of TB is being strongly recommended in the Philippines. However, this study
has shown that the poor quality of many of the X-rays in the field, both public and private, in
industrial and small clinics and hospitals are a major barrier to making an accurate diagnosis.
Other issues include inter-observer variability and pressures on physicians to treat among
other challenges. A shift to digital X-rays will go a long way in addressing quality issues, while
further training of physicians in the proper interpretation of X-rays for TB diagnosis will help
high burden TB countries. A stricter quality assurance should be implemented for use of rou-
tine X-rays.
Limitations
The X-rays obtained in the two sites in both public and private were mostly non-digital, many
were of poor quality. The use of Xpert as the gold standard instead of culture may have missed
some cases because of its lower sensitivity. There may be truly CD cases that are both smear-
negative and Xpert negative. It must also be pointed out however that the EP in this study may
not truly represent TBDCs nationwide.
Conclusion
The impact of Xpert on the diagnosis of confirmed TB is substantial, identifying potentially
31% of smear negative presumptive cases as BC PTB. Clinical and X-ray features among Xpert
positive cases supported the accuracy of Xpert. The EP is likely to have high sensitivity but low
specificity for diagnosing presumptive smear-negative tuberculosis when compared to the
Xpert results. The number of patients enrolled to treatment was not influenced by Xpert
results. There was still a high percentage of smear-negative, Xpert negative cases who were
enrolled to treatment upon the decision of an SP. A combination of factors such as relying on
chest X-ray for diagnosis of SNPT, inclusion criteria of abnormal chest X-ray, implication of
opportunity cost among patients seeking pre-employment clearance contributed significantly
to the high percentage of clinically diagnosed SNPT.
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